title: Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma.
authors.forename: P
authors.initials: P
authors.lastname: Kapoor
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: S J
authors.initials: SJ
authors.lastname: Mandrekar
authors.forename: K M
authors.initials: KM
authors.lastname: Laumann
authors.forename: A
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: M Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: D
authors.initials: D
authors.lastname: Dingli
authors.forename: M A
authors.initials: MA
authors.lastname: Gertz
authors.forename: R A
authors.initials: RA
authors.lastname: Kyle
authors.forename: P R
authors.initials: PR
authors.lastname: Greipp
authors.forename: S V
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002455:Cell Division; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D008940:Mitotic Index; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D010950:Plasma Cells / Q000473:pathology; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide